IGF-1 LR3 (Long R3 IGF-1)
Modified Growth Factor Analog | Muscle Growth
Community Research
Join others researching IGF-1 LR3 — share findings, ask questions, and learn from real experiences
IGF-1 LR3 is a synthetic 83-amino acid analog of insulin-like growth factor-1 that has never been approved for human use. The N-terminal extension and R3 substitution reduce binding protein interaction, maintaining elevated free circulating levels with ~3x greater potency than native IGF-1.
Functions as a full IGF-1 receptor agonist activating PI3K/Akt/mTOR and MAPK/ERK pathways. The modifications prevent protein sequestration, maintaining elevated free circulating levels for extended anabolic effects.
Molecular Data
Research Indications
15-20% lean mass gains in 4 weeks through satellite cell activation (rat studies).
Cancer cachexia rats maintained 30% more muscle versus placebo.
Creates new muscle fibers via satellite cell differentiation.
Accelerated wound healing in animal models.
Enhanced connective tissue repair.
Directs nutrients toward muscle tissue.
Enhanced lipolysis through IGF-1 pathway.
Dosing Protocols
Subcutaneous or intramuscular injection. CRITICAL: Consume 30-60g fast carbohydrates immediately after injection to prevent hypoglycemia. Never inject before sleep.
Beginner Protocol
20-30mcg
Once daily post-workout
SubQ/IM
Intermediate
40-60mcg
Once daily
Advanced
80-100mcg
Once or split AM/PM
Women's Protocol
10-20mcg
Reconstitution Instructions
IGF-1 LR3 lyophilized powder
0.6% acetic acid OR bacteriostatic water
Insulin syringes (29-32 gauge)
Alcohol swabs
1 Equilibrate to room temperature (15-30 min)
2 Sanitize rubber stopper with alcohol
3 Calculate concentration (e.g., 1mg in 2mL = 500mcg/mL)
4 Inject diluent slowly along vial wall
5 Gently swirl - never shake vigorously
6 Allow 2-5 minutes for complete dissolution
7 Store immediately at 2-8°C protected from light
8 Acetic acid reconstitution: stable 1 year
9 BAC water reconstitution: use within 7 days
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Hypoglycemia (lasting up to 30 hours) - CRITICAL
Water retention
Joint stiffness
Muscle soreness
Increased pump during workouts
Stop Signs - Discontinue if:
Severe or recurring hypoglycemia despite carbohydrate intake
Unusual growths, lumps, or rapid mole changes
Severe joint pain or carpal tunnel symptoms
Persistent nausea, headaches, or vision changes
Signs of organ enlargement
Extreme fatigue or mental fog
Contraindications
NEVER approved for human use - research chemical only
Cancer history or undiagnosed growths
May cause organ hypertrophy (heart, intestines)
WADA prohibited - causes failed drug tests
Quality Checklist
Good Signs
HPLC purity >95%
Mass spectrometry confirmation
Cold storage maintained (-20°C lyophilized)
Certificate of analysis from reputable source
Warning Signs
Research chemical status - never approved for human use
Zero human clinical trials exist
Species-specific responses vary significantly
Bad Signs
Severe hypoglycemia risk - life-threatening low blood sugar lasting 20-30 hours
Cancer proliferation concern - UK Biobank links elevated IGF-1 to multiple cancers
Black market quality varies - oxidized and degraded forms common
Frequently Asked Questions
Why is IGF-1 LR3 called 'long R3'?
The N-terminal extension and R3 (arginine) substitution reduce binding to IGF binding proteins, allowing the peptide to circulate freely for 20-30 hours instead of being sequestered. This gives it approximately 3x greater potency and systemic presence than native IGF-1.
Can I take IGF-1 LR3 with HGH?
Not recommended. Both are IGF-1 pathway agonists, and combining them creates excessive IGF-1 levels with amplified side effects including severe hypoglycemia, joint pain, organ enlargement risk, and carpal tunnel symptoms.
How long can I safely use IGF-1 LR3?
Maximum recommended cycle is 4-6 weeks with equal off-time. Prolonged use risks receptor desensitization, excessive organ growth, and cumulative hypoglycemia danger. Most users run 4-6 week cycles with 4-6 weeks off between.
What happens if my blood sugar drops dangerously low on IGF-1 LR3?
Severe hypoglycemia from IGF-1 LR3 can last 20-30 hours due to the long half-life. Consume 30-60g fast carbs immediately after injection and keep glucose tablets handy. Never inject before sleep. Consider having glucagon available for emergency hypoglycemia.
References
LR3IGF-I was approximately 2.5-fold more potent than native IGF-1 in reversing dexamethasone-induced catabolism. 7-day treatment showed significant body weight recovery vs 19g loss in controls.
Fetal plasma insulin concentrations decreased 66% with IGF-1 LR3 infusion during hyperglycemic clamp. Insulin secretion suppression was acute and did not persist in isolated islets.
IGF-1 treatment effectively attenuated host muscle protein and lean tissue depletion in a sarcoma model without stimulating tumor growth. Dose-dependent increases in carcass weight and gastrocnemius muscle protein.
Higher circulating IGF-1 associated with increased risks of colorectal, breast, prostate, and thyroid cancers in the UK Biobank prospective cohort of >395,000 participants.
Related Peptides
Complementary healing mechanisms.
Different repair pathway activation.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.